PMID- 32406910
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20220914
IS  - 1573-4935 (Electronic)
IS  - 0144-8463 (Print)
IS  - 0144-8463 (Linking)
VI  - 40
IP  - 5
DP  - 2020 May 29
TI  - Dexmedetomidine postconditioning suppresses myocardial ischemia/reperfusion 
      injury by activating the SIRT1/mTOR axis.
LID - 10.1042/BSR20194030 [doi]
LID - BSR20194030
AB  - Myocardial ischemia/reperfusion (MI/R) triggers a complicated chain of 
      inflammatory reactions. Dexmedetomidine (Dex) has been reported to be important 
      in myocardial disorders. We evaluated the role of Dex in MI/R injury via the 
      silent information regulator factor 2-related enzyme 1 (SIRT1)/mammalian target 
      of rapamycin (mTOR) signaling pathway. First, Dex was immediately injected into 
      rat models of MI/R injury during reperfusion. After Evans Blue-triphenyl 
      tetrazolium chloride (TTC) and Hematoxylin-Eosin (H-E) staining, MI/R injury was 
      observed. The extracted serum and myocardial tissues were used to detect 
      oxidative stress and the inflammatory response. Western blot analysis was 
      performed to evaluate MI/R autophagy and the levels of proteins associated with 
      the SIRT1/mTOR axis. The effects of the combination of Dex and SIRT1 inhibitor 
      EX527 on MI/R injury and autophagy were evaluated. Finally, the mechanism of Dex 
      was tested, and autophagy levels and the levels of proteins associated with the 
      SIRT1/mTOR signaling pathway were assessed in MI/R rats. The results of the 
      present study suggested that Dex relieved MI/R injury, reduced cardiomyocyte 
      apoptosis, oxidative stress and inflammatory reactions, up-regulated the 
      SIRT1/mTOR axis and decreased overautophagy in MI/R rats. SIRT1 inhibitor EX527 
      attenuated the protective effects of Dex. Our study demonstrated that Dex 
      alleviated MI/R injury by activating the SIRT1/mTOR axis. This investigation may 
      offer new insight into the treatment of MI/R injury.
CI  - (c) 2020 The Author(s).
FAU - Zhang, Xiong
AU  - Zhang X
AD  - Guangzhou First People's Hospital, School of Medicine, South China University of 
      Technology, Guangzhou 510405, Guangdong, P.R. China.
FAU - Li, Yongxing
AU  - Li Y
AD  - Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, P.R. 
      China.
FAU - Wang, Yong
AU  - Wang Y
AD  - The First Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangzhou 510405, Guangdong, P.R. China.
FAU - Zhuang, Yuerong
AU  - Zhuang Y
AD  - The First Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangzhou 510405, Guangdong, P.R. China.
FAU - Ren, Xiaojie
AU  - Ren X
AD  - The First Clinical School, Guangzhou University of Chinese Medicine, Guangzhou 
      510405, Guangdong, P.R. China.
FAU - Yang, Kai
AU  - Yang K
AD  - Department of Anesthesiology, The First Affiliated Hospital of Guangzhou 
      University of Chinese Medicine, Guangzhou 510405, Guangdong, P.R. China.
FAU - Ma, Wuhua
AU  - Ma W
AD  - Department of Anesthesiology, The First Affiliated Hospital of Guangzhou 
      University of Chinese Medicine, Guangzhou 510405, Guangdong, P.R. China.
FAU - Zhong, Ming
AU  - Zhong M
AD  - Department of Anesthesiology, The First Affiliated Hospital of Guangzhou 
      University of Chinese Medicine, Guangzhou 510405, Guangdong, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Retracted Publication
PL  - England
TA  - Biosci Rep
JT  - Bioscience reports
JID - 8102797
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Inflammation Mediators)
RN  - 67VB76HONO (Dexmedetomidine)
RN  - EC 2.7.1.1 (mTOR protein, rat)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.5.1.- (Sirt1 protein, rat)
RN  - EC 3.5.1.- (Sirtuin 1)
SB  - IM
ECI - Biosci Rep. 2022 Jul 29;42(7):. PMID: 35892312
RIN - Biosci Rep. 2022 Sep 30;42(9):. PMID: 36102153
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Antioxidants/*pharmacology
MH  - Apoptosis/drug effects
MH  - Autophagy/drug effects
MH  - Dexmedetomidine/*pharmacology
MH  - Disease Models, Animal
MH  - Inflammation Mediators/metabolism
MH  - Myocardial Infarction/enzymology/pathology/*prevention & control
MH  - Myocardial Reperfusion Injury/enzymology/pathology/*prevention & control
MH  - Myocytes, Cardiac/*drug effects/enzymology/pathology
MH  - Oxidative Stress/drug effects
MH  - Rats, Sprague-Dawley
MH  - Signal Transduction
MH  - Sirtuin 1/*metabolism
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC7253405
OTO - NOTNLM
OT  - Dexmedetomidine
OT  - EX527
OT  - Myocardial ischemia/reperfusion
OT  - SIRT1
OT  - mTOR
COIS- The authors declare that there are no competing interests associated with the 
      manuscript.
EDAT- 2020/05/15 06:00
MHDA- 2021/03/24 06:00
PMCR- 2020/05/27
CRDT- 2020/05/15 06:00
PHST- 2019/12/17 00:00 [received]
PHST- 2020/04/23 00:00 [revised]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/27 00:00 [pmc-release]
AID - 224148 [pii]
AID - BSR20194030 [pii]
AID - 10.1042/BSR20194030 [doi]
PST - ppublish
SO  - Biosci Rep. 2020 May 29;40(5):BSR20194030. doi: 10.1042/BSR20194030.